エピソード

  • CRSP Today - Aug 13: Bank of America Sells Shares

    CRSP Today - Aug 13: Bank of America Sells Shares
    2026/08/13
    Hey there! It’s Joey here, your friendly long-time investor, breaking down what went down with CRISPR Therapeutics today. So, CRSP had a red day, slipping just a tad, down 0.15%. Not a huge drop, but still, nobody likes to see red.

    So, what happened? It looks like Bank of America decided to trim its position in CRISPR. They sold off some shares, and you know how that goes; when a big player makes a move like that, people start hitting the sell button fast. Even though we're talking a minor drop, it can really shake things up, especially when folks are already a bit jittery about the biotech sector.

    Now, let’s chat about the why behind this move. The news from Bank of America was pretty big today, and it’s always a bummer when a major player like that starts pulling back. It creates a ripple effect, and investors start to wonder if there's something deeper going on. There’s also been some talk about CRISPR’s recent financials showing stronger revenue and a narrower loss, which could change the game for folks considering investing. But, with news like the Bank of America sell-off, it’s hard to see the silver lining for now.

    Oh, and here's something worth keeping an eye on: CRISPR’s CFO just gifted 750 shares. That’s kinda interesting, right? It could mean they’re feeling confident about the future, or maybe it's just a nice gesture. Either way, it’s a little tidbit that could spark some curiosity among investors.

    To wrap it up, CRISPR had a bit of a rough day with that Bank of America news. But hey, the biotech world is always a wild ride, and it’s not all doom and gloom. Keep your chin up! Remember, I’m just here sharing the info and having a little fun with the stock talk. No financial advice, just good vibes. Catch you later!
    続きを読む 一部表示
    2 分
  • CRSP Today - Aug 12: Mixed Signals for CRISPR

    CRSP Today - Aug 12: Mixed Signals for CRISPR
    2026/08/12
    Hey there! It’s Joey, your friendly longtime investor, here to break down what went down with CRISPR Therapeutics today. So, CRSP had a bit of a red day, slipping down by half a percent. Yeah, that one stung a little.

    Now, let’s get into the nitty-gritty. The stock barely moved, but there’s some chatter around the company that’s worth mentioning. They reported stronger revenue and a narrower loss, which is usually a good sign. People love to see that kind of progress! But it seems like the market's still trying to figure out what to make of it all. Sometimes, good news doesn’t translate into stock gains right away, and today was one of those days.

    In the background, CRISPR’s CFO, Prasad Raju, made a little splash by gifting 750 shares. That’s kind of a cool move, right? It shows some confidence in the company. Meanwhile, it looks like Quantinno Capital Management is raising its position in CRISPR. That’s definitely something to keep an eye on, as it suggests some folks are still betting on the future here.

    Now, here's a quick fact for you: the FDA recently approved some products for three biotech companies, which is huge news for the industry. This could be a game-changer for CRISPR and its peers, so it’s worth watching how that plays out.

    So, to wrap it up, CRSP had a quiet day, but there’s some interesting stuff happening behind the scenes. Always good to keep your ears to the ground! Remember, this is just for fun and to keep you informed, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • CRSP Today - Aug 11: Small Dip Amid Updates

    CRSP Today - Aug 11: Small Dip Amid Updates
    2026/08/11
    Hey there! It's Joey, your friendly investor buddy, here to break down what went down with CRISPR Therapeutics today. So, CRSP had a bit of a rough day, dipping just a smidge, down about 0.11%. Not a huge drop, but still, a dip is a dip, right?

    Now, what happened? Well, the stock kinda floated around without making any real waves. It opened, traded, and closed pretty much in the same range. Volume was steady, but nothing crazy. Just one of those days where it felt like the market was taking a breather.

    So, why the movement? Honestly, nobody really knows for sure. There were some updates about CRISPR's stock position being raised by Quantinno Capital Management, which usually sounds like good news. But it didn’t really fire up the stock. Plus, there were some mixed vibes in the market about other gene-editing companies like Intellia Therapeutics, which might’ve added to the uncertainty. Sometimes, when one stock's not doing well, it drags others down too.

    And here’s a quick note: there’s been chatter about CRISPR's commercial collaborations and pipeline focus. So, keep an eye on that. Could be something cooking in the background that might shake things up later.

    Alright, that’s the scoop! Just remember, this is all for fun and info—no financial advice here. Catch you later!
    続きを読む 一部表示
    1 分
  • CRSP Today - Aug 10: Update on Collaboration and Pipeline

    CRSP Today - Aug 10: Update on Collaboration and Pipeline
    2026/08/10
    Hey there! I'm Joey, your friendly investor who's been around the block a few times. Today, we’re talking about CRISPR Therapeutics, ticker CRSP. It was a green day, up about 1.66%. Not too shabby!

    So, what happened? The stock had a nice little bump today. It seems like people were feeling optimistic, which is always a good vibe. The trading volume was on point, matching the average, so no wild swings or anything. Just a steady climb.

    Now, why did it move this way? Well, there’s chatter about an update on their commercial collaboration and pipeline focus. That’s a big deal in the biotech world. Investors are curious about where CRISPR is headed, especially with partnerships and new projects in the pipeline. It’s like everyone’s waiting to see if they’re about to drop some exciting news or if things are just status quo.

    Also, on the broader scene, you might’ve heard about Intellia Therapeutics and their recent report. Analysts are cutting estimates for them, which can affect the whole gene-editing space. So, seeing CRSP moving up today could also be a reaction to that. It’s kind of like a ripple effect in the market.

    Looking ahead, there’s buzz about CRISPR’s upcoming announcements. People are keeping an eye on their pipeline updates, and any news could really shake things up.

    Alright, that’s the scoop for today. Always remember, this is just info for you to chew on, not financial advice. Stay curious and keep learning! Catch you later!
    続きを読む 一部表示
    1 分
  • CRSP Today - Aug 09: Earnings Spark Interest

    CRSP Today - Aug 09: Earnings Spark Interest
    2026/08/09
    Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today we’re chatting about CRISPR Therapeutics, or CRSP for short. Today was a green day for them; the stock was up about 3.6%. Not too shabby!

    So, what went down? Well, CRISPR caught some fresh interest after their earnings report. It seems like people are starting to pay attention again. The stock's been hanging around, but this news gave it a little boost. You know how it is—sometimes a solid earnings report can give a stock a second wind.

    Now, why the sudden interest? According to some articles I checked out, there’s chatter out there that CRISPR might actually be undervalued right now. Yeah, you heard that right! Some folks are thinking it could be below fair value, which gets people curious. Also, Wall Street Zen bumped their rating on it to “Hold.” That usually gets a few more eyes on the stock, right?

    But here's the thing—nobody really knows why some stocks jump while others just sit there. It could just be a mix of the earnings report and some positive sentiment floating around. Plus, with all the buzz about gene editing and CRISPR tech, it’s like everyone’s on the lookout for the next big thing.

    Oh, and just so you know, CRISPR has been doing some interesting work lately. They’re still pushing ahead with their research and trials, so there’s definitely stuff happening behind the scenes. That could mean more news and potential movements down the line.

    So, to wrap it up, CRSP had a good day, thanks to some fresh earnings interest and a bit of optimism about its value. Just remember, I’m here to share info and keep you entertained, not to dish out financial advice. Stay smart, keep learning, and I’ll catch you later!
    続きを読む 一部表示
    2 分
  • CRSP Today - Aug 08: Earnings Spark Interest

    CRSP Today - Aug 08: Earnings Spark Interest
    2026/08/08
    Hey there! It’s Joey here, your friendly investor buddy. I’m breaking down the day for CRISPR Therapeutics, and guess what? Today was a green day! The stock was up about 3.6%. Not too shabby, right?

    So, what went down? It seems like CRISPR got a little boost from its earnings report that got people talking. There’s been fresh interest in the stock, which is always a good sign. I mean, who doesn’t love a little excitement in the market? The volume was pretty steady, too, matching the average, so folks were definitely engaged.

    Now, let’s talk about why this happened. Analysts are buzzing about whether CRISPR is actually below its fair value, which could mean there’s some room to grow. H.C. Wainwright is keeping their rating in place, specifically focusing on label expansion, which sounds promising. On the other hand, Goldman Sachs is still hanging in there with a “hold” rating, so it’s kind of a mixed bag of opinions out there. Also, some big players like Dimensional Fund Advisors and Brave Asset Management have trimmed their stakes, but that doesn’t seem to have scared off the rest of the crowd too much.

    Looking ahead, one thing worth noting is that analysts are keeping a close eye on CRISPR's potential label expansion, which could open new doors for the company. If that goes well, it might just keep the positive vibes rolling.

    So, there you have it! A nice little recap of CRISPR’s day. Just remember, this is all for fun and info—no financial advice here. Catch you later!
    続きを読む 一部表示
    1 分
  • CRSP Today - Aug 07: CRISPR Up After Earnings Boost

    CRSP Today - Aug 07: CRISPR Up After Earnings Boost
    2026/08/07
    Hey, what’s up? It’s Joey here! I’ve been in the investing game for years, and today we’re talking about CRISPR Therapeutics. So, CRSP had a pretty solid day, up about 4.2%. Not too shabby, right?

    Alright, here’s the scoop. The stock was buzzing today, and it’s all thanks to some positive vibes coming from their recent earnings report. Analysts are feeling good and are actually lifting their estimates for CRISPR. That’s like a nice little pat on the back for the company. It seems like people are starting to think they might be onto something big with their gene-editing tech.

    Now, why the boost? Well, it looks like H.C. Wainwright, a pretty well-known firm, is sticking with their rating on CRISPR, especially after that earnings report. People love when analysts back a stock, and it sounds like CRISPR is getting some love from the pros. Plus, there’s also some mixed news with funds buying and selling shares. Dimensional Fund Advisors sold a bunch of shares, but California’s State Teachers Retirement System decided to increase their position. It’s like a tug-of-war, but all this activity is creating some buzz around the stock.

    One thing worth mentioning is that analysts seem pretty bullish on healthcare stocks right now. CRISPR is definitely in that mix, which could mean more attention and possibly more action in the coming days.

    So, there you have it! CRISPR is riding high on some positive earnings news and analyst support. Remember, this is just for fun and info; I’m not giving any buy or sell advice here. Stay smart and keep your head in the game. Catch you later!
    続きを読む 一部表示
    1 分
  • CRSP Today - Aug 06: Earnings Beat and Pipeline Buzz

    CRSP Today - Aug 06: Earnings Beat and Pipeline Buzz
    2026/08/06
    Hey there! It’s Joey here, your friendly investor buddy. I’ve been in the game for a while, and today we’re chatting about CRISPR Therapeutics, ticker CRSP. So, how’d they do today? Well, it was a green day, but not by much—just a tiny bump up of about 0.27%.

    Now, what’s the scoop? So, CRISPR dropped their Q2 earnings, and guess what? They beat estimates! That’s always a good sign, right? Their revenues were looking solid, and that kind of news usually gives investors a little boost of confidence. It’s like when you ace a test you thought you’d bomb—definitely a reason to smile.

    But wait, there’s more! The buzz around their drug CASGEVY is heating up, especially after some pipeline updates. People are really excited about its expansion, and it seems to be gaining traction. That’s likely why the stock got a nice little bump earlier in the week—investors are feeling optimistic about its potential. Plus, Piper Sandler is still on board with a "buy" rating for CRSP. That’s like getting a thumbs up from your favorite teacher.

    So, what's on the horizon? Well, there’s chatter about CRISPR’s sales growth for CASGEVY and their in vivo expansion with CTX310. Those are some big moves that could really shape the company’s future.

    In a nutshell, CRISPR is looking solid right now, even if today’s gain was a bit on the chill side. As always, remember: this is just for fun and info—no financial advice here! Catch you later, folks!
    続きを読む 一部表示
    1 分